F11R and central nervous system cancer: Messenger RNA data from the National Cancer Institute REpository for Molecular BRAin Neoplastic Data (NCI REMBRANDT) suggested that high levels of JAM-A are associated with poor outcome in glioma patients, and we recently demonstrated that high JAM-A protein expression is associated with shorter survival in patients with GBM [14].